

*Date:* September 20–21, 2001.

*Open:* September 20, 2001, 1 pm to 1:30 pm.

*Agenda:* To review the Division's scientific and planning activities.

*Place:* National Institutes of Health, 9000 Rockville Pike, Building 31, Conference Room 9A51, Bethesda, MD 20892.

*Closed:* September 20, 2001, 1:30 pm to 3 pm.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 9000 Rockville Pike, Building 31, Conference Room 9A51, Bethesda, MD 20892.

*Open:* September 20, 2001, 3 pm to adjournment.

*Agenda:* To review the Division's scientific and planning activities.

*Place:* National Institutes of Health, 9000 Rockville Pike, Building 31, Conference Room 9A51, Bethesda, MD 20892.

*Open:* September 21, 2001, 8:30 am to 10 am.

*Agenda:* To review the Division's scientific and planning activities.

*Place:* National Institutes of Health, 9000 Rockville Pike, Building 31, Conference Room 9A51, Bethesda, MD 20892.

*Contact Person:* Robert D. Hammond, PhD, Director for Extramural Activities, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 6707 Democracy Blvd., Room 631, MSC 5452, Bethesda, MD 20892–5452, 301–594–8834, [hammondr@extra.niddk.nih.gov](mailto:hammondr@extra.niddk.nih.gov).

*Name of Committee:* National Diabetes and Digestive and Kidney Diseases Advisory Council, Kidney, Urologic and Hematologic Diseases Subcommittee.

*Date:* September 20–21, 2001.

*Open:* September 20, 2001, 1:30 pm to adjournment.

*Agenda:* To discuss project progress review.

*Place:* National Institutes of Health, 9000 Rockville Pike, Building 31, Conference Room 7, Bethesda, MD 20892.

*Closed:* September 21, 2001, 8:00 am to 9:30 am.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 9000 Rockville Pike, Building 31, Conference Room 7, Bethesda, MD 20892.

*Contact Person:* Robert D. Hammond, PhD, Director for Extramural Activities, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 6707 Democracy Blvd., Room 631, MSC 5452, Bethesda, MD 20892–5452, 301–594–8834, [hammondr@extra.niddk.nih.gov](mailto:hammondr@extra.niddk.nih.gov).

*Name of Committee:* National Diabetes and Digestive and Kidney Diseases Advisory Council, Diabetes, Endocrine and Metabolic Diseases Subcommittee.

*Date:* September 20–21, 2001.

*Open:* September 20, 2001, 1:30 pm to 2:30 pm.

*Agenda:* To review the Division's scientific and planning activities.

*Place:* National Institutes of Health, 9000 Rockville Pike, Conference Room 10, Building 31C, Bethesda, MD 20892.

*Closed:* September 20, 2001, 2:30 pm to adjournment.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 9000 Rockville Pike, Conference Room 10, Building 31C, Bethesda, MD 20892.

*Closed:* September 21, 2001, 8 am to 9:30 am.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 9000 Rockville Pike, Conference Room 10, Building 31C, Bethesda, MD 20892.

*Contact Person:* Robert D. Hammond, PhD, Director for Extramural Activities, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 6707 Democracy Blvd., Room 631, MSC 5452, Bethesda, MD 20892–5452, 301–594–8834, [hammondr@extra.niddk.nih.gov](mailto:hammondr@extra.niddk.nih.gov)

Information is also available on the Institute's/Center's home page: [www.niddk.nih.gov/fund/divisions/DEA/Council/coundesc.htm](http://www.niddk.nih.gov/fund/divisions/DEA/Council/coundesc.htm), where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS).

*Dated:* August 17, 2001.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 01–21522 Filed 8–24–01; 8:45 am]

**BILLING CODE 4140–01–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel, ZDK1 GRB–6(03).

*Date:* September 7, 2001.

*Time:* 2 p.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* 6707 Democracy Blvd., Bethesda, MD 20892. (Telephone Conference Call)

*Contact Person:* Dan E. Matsumoto, PhD, Scientific Review Administrator, Review Branch, DEA, NIDDK, room 749, 6707 Democracy Boulevard, National Institutes of Health, Bethesda, MD 20892–6600, (301) 594–8894.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

*Dated:* August 17, 2001.

**LeVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 01–21523 Filed 8–24–01; 8:45 am]

**BILLING CODE 4140–01–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Drug Abuse; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Council on Drug Abuse.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Council on Drug Abuse.

*Date:* September 12–13, 2001.

*Closed:* September 12, 2001, 9 a.m. to 4:30 p.m.

*Agenda:* to review and evaluate grant applications.

*Place:* 6001 Executive Blvd., Room A1/A2, Rockville, MD 20852.

*Open:* September 13, 2001, 9:00 a.m. to 3:30 p.m.

*Agenda:* This portion of the meeting will be open to the public for announcements and reports of administrative, legislative and program developments in the drug abuse field.

*Place:* 6001 Executive Blvd., Room A1/A2, Rockville, MD 20852.

*Contact Person:* Teresa Levitin, PhD, Director, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, Bethesda, MD 20892-9547, (301) 443-2755.

Information is also available on the Institute's/Center's home page: [www.drugabuse.gov/NACDA/NACDAHome.html](http://www.drugabuse.gov/NACDA/NACDAHome.html), where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse Research Programs, National Institutes of Health, HHS)

Dated: August 20, 2001.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 01-21526 Filed 8-24-01; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institution of Neurological Disorders and Stroke; Notice of Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of meetings of the National Advisory Neurological Disorders and Stroke Council.

The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material,

and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Neurological Disorders and Stroke Council, Training Subcommittee.

*Date:* September 12, 2001.

*Time:* 8 p.m. to 10 p.m.

*Agenda:* To discuss the training programs of the Institute.

*Place:* Hyatt Regency, One Metro Center, Bethesda, MD 20814.

*Contact Person:* Constance W. Atwell, PhD, Associate Director for Extramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Neuroscience Center, 6001 Executive Blvd., Suite 3309, MSC 9531, Bethesda, MD 20892-9531, (301) 496-9248.

*Name of Committee:* National Advisory Neurological Disorders and Stroke Council, Clinical Trials Subcommittee.

*Date:* September 13, 2001.

*Open:* 8 a.m. to 8:30 a.m.

*Agenda:* To discuss clinical trials policy.

*Place:* 31 Center Drive, Building 31, Room 8A28, Bethesda, MD 20892.

*Closed:* 8:30 a.m. to 10 a.m.

*Agenda:* To review and evaluate grant applications.

*Place:* 31 Center Drive, Building 31, Room 8A28, Bethesda, MD 20892.

*Contact Person:* Constance W. Atwell, PhD, Associate Director for Extramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Neuroscience Center, 6001 Executive Blvd., Suite 3309, MSC 9531, Bethesda, MD 20892-9531, (301) 496-9248.

*Name of Committee:* National Advisory Neurological Disorders and Stroke Council, Infrastructure, Neuroinformatics, and Computational Neuroscience Subcommittee.

*Date:* September 13, 2001.

*Time:* 8 a.m. to 10 a.m.

*Agenda:* To discuss research mechanisms and infrastructure needs.

*Place:* 31 Center Drive, Building 31, Room 8A52, Bethesda, MD 20892.

*Contact Person:* Robert Baughman, MD, Associate Director for Technology Development, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 6001 Executive Blvd., Suite 2137, MSC 9527, Bethesda, MD 20892-9527, (301) 496-1779.

*Name of Committee:* National Advisory Neurological Disorders and Stroke Council.

*Dates:* September 13-14, 2001.

*Open:* September 13, 2001, 10:30 a.m. to 5 p.m.

*Agenda:* Report by the Acting Director, NINDS; Report by the Director, Division of Extramural Research; and other administrative and program developments.

*Place:* 1 Center Drive, Building 1, Wilson Hall, Bethesda, MD 20892.

*Closed:* September 14, 2001, 8:30 a.m. to 12 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* 1 Center Drive, Building 1, Wilson Hall, Bethesda, MD 20892.

*Contact Person:* Constance W. Atwell, PhD, Associate Director for Extramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Neuroscience Center, 6001 Executive Blvd., Suite 3309, MSC 9531, Bethesda, MD 20892-9531, (301) 496-9248.

Information is also available on the Institute's/Center's home page: [www.ninds.nih.gov](http://www.ninds.nih.gov), where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: August 20, 2001.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 01-21527 Filed 8-24-01; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF JUSTICE

### Notice of Lodging of Consent Decree Pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act and the Comprehensive Environmental Response, Compensation, and Liability Act

In accordance with 28 CFR 50.7 and 42 U.S.C. 9622(i), notice is hereby given that on August 21, 2001, a Consent Decree was lodged with the United States District Court for the District of Puerto Rico in *United States v. Tropical Fruit, S.E., et al.*, Civil Action No. 97-1442-DRD. In the complaint the United States, on behalf of the U.S. Environmental Protection Agency ("EPA"), alleged that the Defendants violated the Federal Insecticide, Fungicide, and Rodenticide Act ("FIFRA"), 7 U.S.C. 136 *et seq.*, and the Comprehensive Environmental Response, Compensation, and Liability Act ("CERCLA"), 42 U.S.C. 9601, *et seq.*, at a Farm located in Rural Zone Boca, Guayanilla, Puerto Rico. The United States' complaint alleged, *inter alia*, that Defendants applied pesticides to agricultural crops, including mangos and bananas, located on the Farm in such a manner that the pesticides drifted or otherwise migrated beyond the boundaries of Defendants' Farm in contravention of the pesticide label requirements.

The Consent Decree requires Defendants to pay \$35,000 in penalties and CERCLA response costs and to comply with extensive injunctive relief measures, including the creation of a buffer zone on the northern and a portion of the western perimeter of the